Korea’s insurance authorities are introducing various measures to reduce drug costs. The government is applying risk-sharing agreements to precalculation drugs and requiring submission of follow-up data for drugs that are exempt from sumitting pharmacoeconomic evaluation data.

The drugs subject to the authorities’ measures are Phesgo SC Inj (pertuzumab/trastuzumab) and Ilaris Solution (canakinumab).

Phesgo is a biobetter that was developed as a fixed-dose subcutaneous injection formulation of the intravenous injected Herceptin and Perjeta to improve dosing convenience and reduce treatment time for breast cancer patients. Since it is approved as an improved biologic, its insurance price